212 results on '"Ende, Marchina"'
Search Results
2. HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
Catalog
Books, media, physical & digital resources
3. The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors
4. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women
5. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
6. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift
7. Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
8. Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors.
9. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients
10. Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 Patients
11. Hepatitis B Surface Antigen Decline and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV
12. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy
13. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption
14. Current and future applications of dried blood spots in viral disease management
15. Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment-Naive Patients: The ATHENA Cohort Study
16. A Prospective Open Study of the Efficacy of High-Dose Recombinant Hepatitis B Rechallenge Vaccination in HIV-Infected Patients
17. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
18. Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus
19. Low Risk of Treatment Failure after Substitution of Nevirapine for Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients with Virus Suppression
20. Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions
21. How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
22. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women
23. Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases
24. Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population
25. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals
26. Photodynamic therapy with systemic meta-tetrahydroxyphenylchlorin in the treatment of anal intraepithelial neoplasia, grade 3
27. HIV-associated Idiopathic Noncirrhotic Portal Hypertension: Risk factors And Association With Didanosine: 1179
28. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy
29. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
30. Early versus Deferred Antiretroviral Therapy for HIV
31. Long-term survival after kidney transplantation in an HIV-positive patient
32. Complete clinical and virological remission of refractory HIV-related Kaposiʼs sarcoma with pegylated interferon alpha
33. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism
34. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
35. Nelfinavir and nevirapine side effects during pregnancy
36. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy
37. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study
38. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients
39. Post-exposure prophylaxis
40. Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
41. Once-daily indinavir plus ritonavir: preliminary results of the PIPO study
42. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
43. Antiretroviral Therapy in Patients with Dual Infection with Human Immunodeficiency Virus Types 1 and 2
44. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
45. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
46. Substituting nevirapine for protease inhibitors because of intolerance
47. CD4 T cells remain the major source of HIV-1 during end stage disease
48. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
49. HIV-2 infection in 12 European residents: virus characteristics and disease progression
50. Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.